

Primucell FIP Lyophilisat und Lösungsmittel zur Herstellung einer intranasalen Suspension für Katzen

Authorised

- Feline coronavirus, strain DF2-ts, Live

Product identification

Medicine name:

Primucell FIP Lyophilisat und Lösungsmittel zur Herstellung einer intranasalen Suspension für Katzen

Active substance:

Feline coronavirus, strain DF2-ts, Live

Target species:

Cat

Route of administration:

Nasal use

Product details

Active substance and strength:

Feline coronavirus, strain DF2-ts, Live

63095.00 50% tissue culture infectious dose / 1.00 Dose

Pharmaceutical form:

Nasal drops, lyophilisate and solvent for suspension

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI06AD02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Germany

Available in:

Germany

Package description:

Available only in [German](#)

Available only in [German](#)

Available only in [German](#)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Deutschland GmbH

Marketing authorisation date:

2/01/2006

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

Paul-Ehrlich-Institut

Authorisation number:

426a/91

Date of authorisation status change:

5/06/2014

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.